

HR 3105

Opioid Treatment Surge Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 5, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 6, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3105>

Sponsor

Name: Rep. Bonamici, Suzanne [D-OR-1]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 6, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 1662	Identical bill	May 23, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jun 5, 2019)

Opioid Treatment Surge Act

This bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.

Actions Timeline

- **Jun 6, 2019:** Referred to the Subcommittee on Health.
- **Jun 5, 2019:** Introduced in House
- **Jun 5, 2019:** Referred to the House Committee on Energy and Commerce.